Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes.

Author: HornbuckleK, MontoA S, OhmitS E, PearceC L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Rimantadine, when used for long-term influenza A (H3N2) prophylaxis in vaccinated elderly residents, showed a trend towards efficacy in reducing clinical and laboratory-confirmed influenza-like illness. This effect was observed at both 100 and 200 mg/day dosages, suggesting relative safety and efficacy in this population.
Paper Details　
Original Abstract of the Article :
The safety and efficacy of rimantadine for long-term prophylaxis of influenza A (H3N2) infection were evaluated among elderly residents in 10 nursing homes. Within each nursing home, participating residents were randomly assigned to receive placebo or rimantadine at 100 or 200 mg/day. Residents were...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1128/AAC.39.10.2224

データ提供：米国国立医学図書館（NLM）

The Effectiveness of Rimantadine for Influenza Prophylaxis in Nursing Homes

This research dives into the world of [influenza prevention] in the vulnerable population of nursing homes. The study used a [randomized control trial] to evaluate the efficacy of rimantadine for preventing influenza A (H3N2) infections. The researchers discovered that rimantadine demonstrated a [potential protective effect] in vaccinated elderly individuals, suggesting that it could act as a [supplementary barrier] against influenza. A significant finding was that a lower dosage of 100mg/day was found to be just as effective as the higher 200mg/day dosage. This finding highlights the importance of [optimizing medication dosages] for different populations.

Rimantadine as a Potential Tool for Influenza Prevention

The study's results suggest that rimantadine, when used alongside vaccination, could be a valuable tool for reducing the risk of influenza-like illness in nursing homes. The researchers found that rimantadine reduced the risk of clinical influenza-like illness by 58% (P=0.079) compared to the placebo group.

A Focus on the Elderly

This research emphasizes the importance of [individualized care] for the elderly, especially in the context of disease prevention. It highlights that a one-size-fits-all approach to medication may not be optimal for all individuals. The findings suggest that further exploration of dosage adjustments and the potential benefits of rimantadine in elderly populations could lead to [improved health outcomes] in this vulnerable group.

Dr.Camel's Conclusion

This research sheds light on the importance of finding the right medication at the right dose, especially when it comes to protecting vulnerable groups like the elderly in nursing homes. It's like trying to find the perfect oasis in a vast desert - finding the right dosage is crucial for maximizing the benefits of medication while minimizing potential risks. This study suggests that rimantadine holds promise as an additional weapon in our arsenal against influenza, but further research is crucial to ensure its safety and effectiveness in the long run.

Date :
  1. Date Completed 1996-06-10
  2. Date Revised 2021-05-26
Further Info :

Pubmed ID

8619572

DOI: Digital Object Identifier

10.1128/AAC.39.10.2224

Related Literature

Article Analysis
・Side Effects of rimantadine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.